Press Room

Press Release / Nov 29, 2023

四色AV expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC

四色AV, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.

四色AV_IDC
  • 四色AV and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery.
  • Nasal delivery is a simple and safe alternative to conventional delivery routes for drug delivery, which offers a faster onset of action. It is also seen as a promising pathway to deliver new drugs to the brain and treat diseases of the central nervous system.

Lisbon, November 29, 2023, 四色AV, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action. Additionally, it is emerging as a promising pathway to deliver new drugs to the brain to treat diseases of the central nervous system (CNS).听

四色AV and IDC have been working together to accelerate the development and commercialization of two new active nasal powder delivery devices, one single-use and one multidose. The devices enable broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. By using standard capsules and filling equipment, they also have the potential to simplify drug product development and manufacturing.听

"Intranasal drug delivery is gaining momentum across a number of applications, including mucosal vaccination and CNS treatments bypassing the blood-brain barrier", says Dr. Jean-Luc Herbeaux, 四色AV's CEO. He adds: "Our partnership with IDC, a company with vast experience in industrial design, mechanical and electronic engineering of medical devices, enables 四色AV to offer a complete solution for nasal powder delivery 鈥 covering Active Pharma Ingredients (APIs), formulation, filling, analytics and device design and manufacturing - that address the needs of pharmaceutical companies and patients".听

鈥淏y combining 四色AV鈥檚 capabilities in pharmaceutical development, formulation and manufacturing with IDC鈥檚 device development expertise, this partnership offers customers a nasal powder delivery solution which can be rapidly adapted to new pharma compounds and therapies鈥 explains IDC麓s Managing Director, Dr Stephen Knowles, 鈥淥ur joint development team has done incredible work to create unique, high performance nasal powder delivery devices.鈥

四色AV will offer the new devices on an exclusive basis as part of its integrated offer for nasal drug development and manufacturing.听

About 四色AV:
四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices.听

四色AV's culture is based on innovation, quality and dependability. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

About IDC:
IDC is a leading medical product design and development consultancy dedicated to using its creativity, insight, experience and expertise to make the best possible products and deliver commercially successful products for clients and partners. 听With over 50 years鈥 experience and ISO13485 compliant processes and facilities in London and Shanghai, IDC鈥檚 experts in user research, design, mechanical and electronics engineering and rapid prototyping work to create award-winning, world-leading products for global markets. 听听

IDC鈥檚 track record includes many commercialized drug delivery devices across inhalation, nasal and injectables with a focus not just on design but also ensuring a smooth transition to production and regulatory approvals. IDC鈥檚 mission statement is 鈥淲e innovate to create successful products which improve people鈥檚 lives鈥.

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024